Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | AATK-AS1 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | ABCC1 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0003 |
mRNA | ABCC3 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0001 |
mRNA | ABCC8 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
mRNA | ABCD4 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
mRNA | ABHD17B | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-09 |
mRNA | ABL2 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0004 |
mRNA | ABLIM2 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
mRNA | ABLIM3 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0004 |
mRNA | ABRACL | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-06 |